CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease
Year: 2011
Type: article
Abstract: The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia chromosome negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20-positive and -negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia chromosome negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20-positive and -negative and positive patients.
Source: Haematologica
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Azienda Sanitaria dell'Alto Adige, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, IRCCS Ospedale San Raffaele, Ospedale dell' Angelo, University of Milan, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Azienda Ospedaliero Universitaria San Giovanni Battista
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2062399441